Specific Antiviral Drugs for COVID 19 Market Report 2024 (Global Edition)

Global Specific Antiviral Drugs for COVID 19 Market Report 2024 Market Size Split by Type (Tablet, Injection), by Route of Administration (Oral, Parenteral), by Application (Mild Symptom Patient, Crit...

Specific Antiviral Drugs for COVID 19 Market Report Description

We have various report editions of Specific Antiviral Drugs for COVID 19 Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Specific Antiviral Drugs for COVID-19 Market

The competitive landscape of the Specific Antiviral Drugs for COVID-19 market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established manufacturers, specialized Specific Antiviral Drugs for COVID-19 companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

August 2020: Zydus has introduced Remdac (Remdesivir) for treating COVID-19 in India. Priced at Rs. 2800 per 100 mg vial, Remdac stands as the most cost-effective Remdesivir brand available in the country. (Source: https://zyduslife.com/public/pdf/Covid_19_Booklet_04_10_21_ZyCoV_D_New_Cover_Page.pdf )

Top Companies Market Share in Specific Antiviral Drugs for COVID 19 Industry: (In no particular order of Rank)

• Sanofi
• Novartis
• Shanghai Zhongxisanwei
• Teva
• Zydus Cadila
• Mylan
• Apotex
• Advanz Pharma
• Sun Pharma
• Kyung Poong
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Specific Antiviral Drugs for COVID-19 Market

Which Region Dominates the Specific Antiviral Drugs for COVID-19 Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. North America benefits from a robust healthcare infrastructure, including state-of-the-art research facilities, extensive clinical trial networks, and efficient distribution channels. In 2022, health spending in the U.S. rose by 4.1% to reach $4.4 trillion, equating to $13,493 per capita. This growth rate mirrors pre-pandemic levels (4.1% in 2019). Notably, health spending accounted for 17.3% of GDP in 2022, resembling pre-pandemic figures (17.5% in 2019) following increases in 2020 (19.5%) and 2021 (18.2%). These factors collectively facilitate the development, evaluation, and dissemination of specific antiviral drugs, thereby fostering market expansion.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Specific Antiviral Drugs for COVID-19 market due to several compelling reasons. ? Despite attempts to control the virus, numerous countries in the Asia Pacific region continue to grapple with significant numbers of COVID-19 cases. By October 20, 2023, India had reported over 44 million confirmed cases of COVID-19. In Maharashtra alone, there were more than 8.1 million confirmed cases, accompanied by over 148 thousand fatalities and over eight million recoveries. This ongoing challenge underscores the urgent need for effective antiviral treatments to manage the disease and alleviate its impact on public health.

The current report Scope analyzes Specific Antiviral Drugs for COVID 19 Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Specific Antiviral Drugs for COVID 19

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size was estimated at USD XX Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Specific Antiviral Drugs for COVID-19 market with a market size of USD XX million in 2024 and is projected to grow at a CAGR of 3.0% during the forecast period. The demand is amplified by the nation's Increased Healthcare Spending, allowing for substantial investment in COVID-19 treatment research and development.
• The Canada Specific Antiviral Drugs for COVID-19 market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. Canada's robust healthcare infrastructure with state-of-the-art medical facilities, and advanced research centers to increased usage of Specific Antiviral Drugs for COVID-19.
• The Mexico Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD XX million in 2024.

Europe Specific Antiviral Drugs for COVID 19

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size was estimated at USD XX Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.5% from 2024 to 2031.

• The United Kingdom Specific Antiviral Drugs for COVID-19 market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 4.3% during the forecast period. In the UK, Specific Antiviral Drugs for COVID-19 sales witness an upswing due to the nation's thriving pharmaceutical industry with companies actively engaged in developing and commercializing specific antiviral drugs for COVID-19.
• The France Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 2.7% during the forecast period with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the Germany Specific Antiviral Drugs for COVID-19 market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 3.7% during the forecast period. In Germany, Specific Antiviral Drugs for COVID-19 sales surge due to rapid development and approval of new antiviral drugs for COVID-19 treatment.
• The Italy Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD XX million in 2024.
• The Russia Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD XX million in 2024.
• The Spain Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 2.6% during the forecast period with a market size of USD XX million in 2024
• The Luxembourg Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD XX million in 2024.
• The Portugal Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 3.3% during the forecast period with a market size of USD XX million in 2024.
• The Greece Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD XX million in 2024.
• Rest of Europe Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 2.2% during the forecast period with a market size of USD XX million in 2024.

Asia Pacific Specific Antiviral Drugs for COVID 19

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size was estimated at USD XX Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Specific Antiviral Drugs for COVID-19 market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Specific Antiviral Drugs for COVID-19 sales surged in China due to the Government's investment in strengthening healthcare infrastructure, including the expansion of hospitals, clinics, and healthcare facilities.
• The Japan Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD XX million in 2024.
• The India Specific Antiviral Drugs for the COVID-19 market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. The demand is augmented by India's significant investments in research and development to develop more effective antiviral drugs for COVID-19.
• The South Korea Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 6.1% during the forecast period with a market size of USD XX million in 2024.
• The Australia Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD XX million in 2024.
• The South East Asia Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 8.0% during the forecast period with a market size of USD XX million in 2024.
• The Rest of Asia Pacific Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 6.8% during the forecast period with a market size of USD XX million in 2024.

South America Specific Antiviral Drugs for COVID 19

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size was estimated at USD XX Million out of which Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Specific Antiviral Drugs for COVID-19 market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Specific Antiviral Drugs for COVID-19 sales flourished in Brazil due to the growing healthcare infrastructure.
• Argentina Specific Antiviral Drugs for COVID-19 market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. The demand is augmented by Argentina's rising prevalence of chronic diseases.
• Colombia Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD XX million in 2024.
• Peru Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 4.6% during the forecast period with a market size of USD XX million in 2024.
• Chile Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD XX million in 2024.
• The Rest of Latin America Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD XX million in 2024.

Middle East and Africa Specific Antiviral Drugs for COVID 19

According to Cognitive Market Research, the global Specific Antiviral Drugs for COVID-19 market size was estimated at USD XX Million out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.

• The GCC Countries Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD XX million in 2024. Specific Antiviral Drugs for COVID-19 sales flourished due to the investment in research and development for COVID-19 treatments, including specific antiviral drugs.
• The Egypt Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 5.0% during the forecast period with a market size of USD XX million in 2024.
• The South Africa Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD XX million in 2024. Specific Antiviral Drugs for COVID-19 sales flourish in South Africa due to investing in strengthening epidemiological surveillance systems and monitoring mechanisms.
• The Turkey Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD XX million in 2024.
• The Nigeria Specific Antiviral Drugs for COVID-19 market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD XX million in 2024.
• The Rest of the specific Antiviral Drugs for the COVID-19 market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD XX million in 2024.

Specific Antiviral Drugs for COVID 19 Market Analysis

How are Segments Performing in the Global Specific Antiviral Drugs for COVID-19 Market?

Specific Antiviral Drugs for COVID-19 Market Type Segment Analysis

According to Cognitive Market Research, Injection stands out as the dominating type. Injections provide a direct and efficient means of delivering antiviral drugs, ensuring rapid bloodstream absorption and swift action against the virus. They are frequently favored for COVID-19 patients requiring hospitalization, especially those with severe symptoms, as they can be administered by healthcare professionals in clinical settings, ensuring precise dosage and monitoring.

Tablet emerges as the fastest-growing category in the Specific Antiviral Drugs for COVID-19 market. Tablets offer the convenience of oral administration, making them an attractive option for patients. This non-invasive route is particularly advantageous for individuals with mild to moderate COVID-19 symptoms who can self-manage their illness at home. Tablets are also well-suited for early intervention strategies aimed at halting disease progression and alleviating symptom severity in COVID-19 patients.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Specific Antiviral Drugs for COVID 19 Industry. Request a Free Sample PDF!

Specific Antiviral Drugs for COVID-19 Market Route of Administration Segment Analysis

According to Cognitive Market Research, the dominating Route of Administration is Oral. Patients often favor the oral route due to its convenience and non-invasive nature, enabling them to self-administer medications at home without medical oversight. This is particularly attractive for individuals with mild to moderate COVID-19 symptoms.

The fastest-growing Route of Administration in the Specific Antiviral Drugs for COVID-19 market is Parenteral. Parenteral administration, on the other hand, entails delivering antiviral drugs directly into the bloodstream, circumventing the gastrointestinal tract. This facilitates rapid absorption and widespread distribution of the medication within the body, resulting in prompt antiviral effects.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Specific Antiviral Drugs for COVID 19 Application Segment Analysis

Application Segment Analysis

According to Cognitive Market Research, the dominating Application is Mild Symptom Patients. Administering antiviral drugs early in patients with mild symptoms aims to halt disease progression to severe stages. By targeting the virus during its early replication, these medications can potentially lessen symptom severity and duration, as well as mitigate the risk of complications. For individuals with mild symptoms, these drugs work to diminish viral load and ease symptoms, fostering a speedier recovery.

The fastest-growing Application in the Specific Antiviral Drugs for COVID-19 market is Critically ill Patient. Critically ill COVID-19 patients necessitate intensive medical intervention to address severe respiratory distress, organ failure, and other life-threatening issues. Specific antiviral drugs tailored to combat the virus are integral components of comprehensive treatment plans for these patients. In critically ill individuals, these medications are employed to directly combat the virus and deter the development of further complications, thereby potentially enhancing patient outcomes.

• Mild Symptom Patient
• Critically Ill Patient

Specific Antiviral Drugs for COVID 19 Distribution Channel Segment Analysis

Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominating Distribution Channel is Hospital Pharmacies. Hospital pharmacies act as central distribution centers for medications, including specific antiviral drugs for COVID-19, ensuring their availability to healthcare providers within the hospital setting. They also play a vital role in providing patient education and counseling on the proper use of these medications.

The fastest-growing Distribution Channel in the Specific Antiviral Drugs for COVID-19 market is Retail Pharmacies. Retail pharmacies serve as convenient points of access for patients seeking medications, including specific antiviral drugs for COVID-19, within their local communities. With their widespread presence, patients can easily obtain these medications close to home without the need for hospital visits or appointments, enhancing convenience and accessibility.

• Hospital Pharmacies
• Retail Pharmacies
• Others

Author's Detail

Vinayak Bali

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

Catering to tailored needs of clients in Consulting, Business Intelligence, Market Research, Forecasting, Matrix-Modeling, Data Analytics, Competitive Intelligence, Primary research and Consumer Insights.

Author's Conclusion